克隆性造血与新冠发心肌炎和心包炎风险
IMPORTANCE: Clonal hematopoiesis of indeterminate potential (CHIP) is the age-related clonal expansion of hematopoietic stem cells with leukemia-associated mutations. Certain CHIP mutations promote atherosclerosis and heart failure through immune-related pathways.…
要点
- 任何CHIP(VAF≥2%)与新发心肌炎/心包炎复合终点风险增加相关(HR 1.75)。
- 大CHIP(VAF≥10%)风险更高(HR 2.07),DNMT3A与心包炎、TET2与心肌炎关联显著。
- CHIP与心肌炎/心包炎的关联强于冠心病和心力衰竭,提示免疫通路介导。
核心结论
- 在中老年人群中,CHIP是心肌炎和心包炎的强风险因素。
- 靶向CHIP及其下游通路可能是预防或治疗心包炎和心肌炎的策略。
研究设计与样本
- 观察性人群队列研究,使用英国生物银行数据,纳入2006-2010年入组、有全外显子测序、无 prevalent 心血管疾病或血液恶性肿瘤且协变量完整的参与者。
- 随访中位13.6年(IQR 12.8-14.2),分析时间2024年11月至2025年7月。
主要发现
- CHIP与心肌炎和心包炎的关联强于与其他心血管疾病(如冠状动脉疾病和心力衰竭)的关联。
临床怎么用
- 对于携带CHIP的中老年患者,应关注心肌炎和心包炎的早期症状,考虑纳入风险监测。
- CHIP可能作为免疫相关心血管炎症风险的标志物,未来或可指导靶向预防策略。
局限性
- 观察性研究设计,不能完全排除残余混杂。
- 心肌炎和心包炎事件数较少(382例),部分亚组分析置信区间较宽。
- 研究人群主要为英国生物银行参与者,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Clonal hematopoiesis of indeterminate potential (CHIP) is the age-related clonal expansion of hematopoietic stem cells with leukemia-associated mutations. Certain CHIP mutations promote atherosclerosis and heart failure through immune-related pathways. OBJECTIVE: To test whether CHIP is associated with the development of myocarditis and pericarditis. DESIGN, SETTING, AND PARTICIPANTS: This observational population-based cohort study used data from the UK Biobank. Enrollment occurred between 2006 and 2010. Participants with whole-exome sequencing, no prevalent cardiovascular disease or hematological malignancy, and complete covariate data were included. Follow-up occurred for a median of 13.6 (IQR, 12.8-14.2) years. Analyses were conducted from November 2024 to July 2025. EXPOSURES: Any CHIP (variant allele frequency [VAF] ≥2%) and large CHIP (VAF ≥10%) constituted coprimary study exposures. Secondary analyses considered DNMT3A and TET2 CHIP as separate exposures. MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of incident myocarditis and pericarditis. Cox regression tested associations of CHIP with myocarditis and pericarditis, adjusting for age, sex, race and ancestry, and cardiovascular risk factors. Secondary analyses considered myocarditis and pericarditis as separate outcomes. Additional analyses compared associations of CHIP with myocarditis and pericarditis with those with other cardiovascular diseases, and tested the bidirectional associations between CHIP and noncardiac immune-mediated inflammatory diseases. RESULTS: Among 335 426 participants (mean age, 56.1 years; 185 429 female [55.3%] and 149 997 male [44.7%]), 11 057 had any CHIP (3.3%), 7271 had large CHIP (2.2%), and 382 developed myocarditis or pericarditis (0.11%). Any and large CHIP were associated with multivariable-adjusted hazard ratios of 1.75 (95% CI, 1.14-2.68; P = .01) and 2.07 (95% CI, 1.28-3.33; P = .003), respectively, for the primary composite outcome of incident myocarditis and pericarditis. Increased risks were observed for DNMT3A and TET2 CHIP, with hazard ratios of 2.22 (95% CI, 1.17-4.21; P = .01) for DNMT3A with pericarditis and 3.65 (95% CI, 1.16-11.49; P = .03) for TET2 with myocarditis. CHIP associated with myocarditis and pericarditis more strongly than with other cardiovascular diseases (eg, coronary artery disease and heart failure). Any CHIP was also associated with 1.27-fold risk (95% CI, 1.16-1.39; P < .001) of developing noncardiac immune-mediated inflammatory diseases, without evidence for reverse causation. CONCLUSIONS AND RELEVANCE: In this study, CHIP was a strong risk factor for myocarditis and pericarditis among middle-aged adults. Targeting CHIP and its downstream pathways may represent a strategy for preventing or treating pericarditis and myocarditis.
引用
- Schuermans A, Flynn S, Niroula A, et al. Clonal Hematopoiesis and Risk of New-Onset Myocarditis and Pericarditis. JAMA Cardiol. 2025. PMID: 40884495. doi:10.1001/jamacardio.2025.3369
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。